Skip to main content

Table 1 Neutralization sensitivity of primary HIV-1 Envs with variable macrophage tropism to gp120 mAbs, soluble CD4, and a broadly neutralizing HIV-infected patient serum

From: Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12

Patient

Tissuea

Env clone

MDM entryb

b12 IC50c

b6 IC50c

sCD4 IC50c

PS IC50c

MACS2

FL

8–12

35478

3.37

> 20

1.03

80.9

  

9–15

1765

1.15

> 20

0.22

76.4

 

LN

10–15

13001

0.99

> 20

> 20

< 50

 

SP

6–18

59224

10.89

> 20

> 20

< 50

MACS3

FL

12–27

13810

> 20

1.87

1.10

< 50

  

5

3402

> 20

6.78

0.40

< 50

 

LN

2

1957

> 20

> 20

3.22

< 50

  

20

16658

> 20

> 20

> 20

< 50

UK1

FL

2–13b

4378

0.05

> 20

5.44

< 50

 

SP

6–20

812689

0.03

> 20

2.39

124.2

  

20

35723

0.03

> 20

0.27

230.2

UK7

FL

6–24

9659

5.53

> 20

7.68

145

  

1–4

13207

11.37

> 20

> 20

128

 

isolate

br34

496588

0.26

> 20

0.45

332.2

 

LN

7–6

5260

5.55

> 20

> 20

< 50

controls

 

YU2

38052

5.47

> 20

1.14

72.4

  

YU2 N386D

114755

2.79

> 20

0.45

115.2

  

JRFL

215305

0.18

> 20

3.72

107.3

  

JRFL N386D

320642

0.09

> 20

6.05

92.7

  1. a FL, frontal lobe (brain); LN, lymph node; SP, spleen
  2. b Luciferase activity in monocyte-derived macrophages (MDM) infected with pseudotyped luciferase-expressing reporter viruses [10, 14].
  3. c mAb (μg/ml), soluble CD4 (sCD4; μg/ml), or HIV-infected patient serum (PS; reciprocal serum dilution) concentration at which luciferase expression was reduced by 50% compared to infection in the absence of mAb (IC50).